Feb 25, 2021 / 10:00PM GMT
Daina Michelle Graybosch - SVB Leerink LLC, Research Division - MD & Senior Research Analyst
Hi, everyone. Welcome to the last session of the day. We're ending in California again. I see a beautiful light, and Scott tells me, and ocean out the window. So a little jealous here looking up on snow in Brooklyn. But we are really excited, and I always enjoy my conversation with Fate Therapeutics, who has about just a few dozen things going on. So we will easily fill the half an hour.
(Operator Instructions) Make it a good question though, because I have some ones I want to get to, too.
Questions and Answers:
Daina Michelle Graybosch - SVB Leerink LLC, Research Division - MD & Senior Research AnalystSo maybe we'll start with an easy question. I know most people are very familiar with Fate. But just in case there are some who are watching that are not, can you remind us, Fate has, at its core, the induced pluripotent stem cell platform and you derive your products from that. Can you remind us why iPSC, you believe, will transform cell therapy.
Trustpilot
